RT Journal Article
SR Electronic
T1 Prioritizing the first doses of SARS-CoV-2 vaccine to save the elderly: the case study of Italy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.26.21252538
DO 10.1101/2021.02.26.21252538
A1 Pontrelli, Giuseppe
A1 Cimini, Giulio
A1 Roversi, Marco
A1 Gabrielli, Andrea
A1 Salina, Gaetano
A1 Bernardi, Stefania
A1 Rocchi, Francesca
A1 Simonetti, Alessandra
A1 Giaquinto, Carlo
A1 Rossi, Paolo
A1 Labini, Francesco Sylos
YR 2021
UL http://medrxiv.org/content/early/2021/03/02/2021.02.26.21252538.abstract
AB Many countries are currently facing high mortality caused by the circulation of SARS-CoV-2 among the elderly not yet vaccinated. Vaccine shortage poses relevant challenges to health authorities, called to act in a timely manner, and with scarcity of vaccine, and data. We have developed a model for estimating the impact of vaccination on the mortality of the elderly following a schedule of mRNA SARS-CoV-2 vaccine that prioritize first dose administration, as alternative to the standard schedule of two doses administered 3 to 4 weeks apart. We studied the Italian scenario, considering it representative of other Countries facing similar conditions in terms of virus circulation, mortality, and vaccine shortage, in the period from February, 10 to April, 14 2021. Under different conditions of quantity of vaccine administration, the schedule prioritizing first doses showed always significant increase of protected individuals, and a decrease of deaths, up to 19.8% less than the standard schedule. These findings support the vaccination option of prioritizing first dose in the elderly until vaccine supplies are adequate.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB/oversight body needed. Data used were aggregated and publicly accessible.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOriginal data needed for building the dataset and the model are publicly available, at the links reported in Bibliography.